Patent classifications
G01N33/53
METHOD FOR PREPARING A BIOLOGICAL SAMPLE FOR USE IN AN IMMUNOLABELING PROCESS
The present invention generally relates to method for preparing a biological sample for use in an immunolabeling process. The invention also relates to corresponding kits for use in the immunolabeling process.
METHOD FOR THE FORMATION AND USE OF AN IMMUNOLABELING COMPLEX
The present invention generally relates to method for forming an immunolabeling complex, the immunolabeling complex comprising a labeled monovalent biotin-binding composition. The invention also related to the use of the antibody-reporter molecule complex for detecting a target in a sample.
PHOSPHOR-INTEGRATED NANOPARTICLES USED IN FLUORESCENCE OBSERVATION
The present invention may provide phosphor-integrated nanoparticles whose precipitation and/or aggregation, particularly aggregation can be inhibited upon carrying out immunostaining therewith and which can thus be used for staining even after long-term storage without requiring a complicated operation, the phosphor-integrated nanoparticles preferrably maintaining excellent performance, such as staining properties, even after long-term storage. The phosphor-integrated nanoparticles of the present invention have an average sphericity (f) of 0.80 to 0.95 and preferably have an average circumference ratio (R) of 0.50 to 0.95. More preferably, the matrix of the particles contains an organic compound, the phosphor-integrated nanoparticles have an average particle size of 300 nm or less, and a biological component-binding molecule is bound on the particle
Target Analysis Chip and Target Analysis Method
The present invention provides a novel target analysis chip and analysis method for directly detecting a target such as a microRNA without performing PCR.
METHODS FOR ALLERGY DIAGNOSIS
Provided herein are improved methods for diagnosing allergy in a subject using designed ankyrin repeat proteins (“DARPins”), and kits for use in such methods. Also provided herein are novel DARPins and methods of use thereof.
MICROSCOPE-FREE IMAGING
Provided herein, in some aspects, are methods of imaging molecules without a microscope or other specialized equipment, referred to herein as “microscope-free imaging (MFI).” Herein, “molecular instruments” (e.g., DNA-based and protein-based molecules) are used, instead of microscopes, in a “bottom-up” approach for inspecting molecular targets.
Examination method for prediction of effect of treatment of cancer based on detection of cancer/testis antibodies
[Object] To provide a novel examination method for a cancer treatment effect, screening method for a peptide for a cancer vaccine, and peptide and composition for inducing an immune response against cancer. [Solving Means] Provided are an examination method for a cancer treatment effect and a screening method for a peptide for a cancer vaccine each including detecting an antibody against a cancer/testis antigen or an anti-p53 antibody in a sample. It is suitable that an anti-XAGE1 antibody (IgG and/or IgA) be detected, or an anti-NY-ESO-1 antibody (IgG) be detected. Also provided are a novel peptide and novel composition for inducing immune responses against cancer.
Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of brain injuries, especially mild traumatic brain injury (mTBI) or concussion, are based upon detection of changes in levels of certain protein biomarkers in a subject undergoing testing, or upon detection of changes in levels of certain protein biomarkers in conjunction with neuroimaging analyses to detect changes in vascular or blood brain barrier (BBB) permeability in the brain, or to detect damage to fiber tracts in the brain, in which changes in biomarker levels correlate with detection of changes in BBB permeability or in brain fiber tract or white matter damage in a subject with brain injury such as mTBI or concussion.
Methods of detecting anti-leptin neutralizing antibodies
Provided herein are methods for detecting neutralizing antibodies to leptins, including metreleptin, as well as identifying subjects having such neutralizing antibodies.
Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.